Tasimelteon for non-24-hour sleep–wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials -

Tasimelteon for non-24-hour sleep–wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials
Information type: Randomised controlled trials
Source: Lancet Public Health
Specialities: Endocrine system disorders
Summary
Two small RCTs found that once-daily tasimelteon can synchronise totally blind people with non-24-hour sleep–wake disorder, however, continued treatment is necessary to maintain any clinical benefits.
UKMi comment
Tasimelteon (Hetlioz), a melatonin agonist, has recently been approved in EU for the treatment of non-24-hour sleep-wake disorder in the totally blind.
Related links: Comment